KineMed, Pfizer Launch Collaboration
News Jan 05, 2016
KineMed Inc. has announced that it has entered into a strategic collaboration with Pfizer Inc. to discover and develop novel proprietary biomarkers in various fields of unmet medical need. KineMed’s platform technology provides a proprietary, rate-based approach for developing novel biomarkers. By utilizing mass spectroscopy and stable isotope labeling of protein turnover, KineMed biomarkers provide rates of change of key proteins involved with therapeutic efficacy and target engagement.
Under the terms of the agreement, Pfizer has licensed access to the KineMed platform and rights to pursue discovery, development and potential commercialization of kinetic biomarkers in various fields. Both companies will work together on discovery research of novel biomarkers, and Pfizer will be responsible for the development and potential commercialization of any novel biomarkers or companion diagnostics for the Pfizer-selected targets.
KineMed will receive an upfront payment, as well as funding for research and development costs associated with Pfizer-selected targets. In addition, KineMed is eligible to receive development and regulatory milestone payments.
“We believe our kinetic biomarker platform provides real advantages over other approaches to biomarker discovery in de-risking and advancing medicines development, and this collaboration with Pfizer is an important step toward helping us realize the full potential of this technology,” said Patrick Doyle, President at KineMed.
Putting Proteins in Their Proper PlaceNews
Everything in the cell has its right place. This includes certain molecules called RNA-binding proteins. When these are misplaced, they can end up causing dangerous clumps that are typical of diseases like ALS. A new study has found a way to send these proteins home.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018